PMID- 18992636
OWN - NLM
STAT- MEDLINE
DCOM- 20081230
LR  - 20181113
IS  - 1873-4456 (Electronic)
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 187
IP  - 1
DP  - 2008 Nov
TI  - Amplification of the BP1 homeobox gene in breast cancer.
PG  - 19-24
LID - 10.1016/j.cancergencyto.2008.07.004 [doi]
AB  - The homeobox gene BP1 is expressed in over 80% of breast cancers and is 
      associated with tumor progression and invasion. However, the mechanism of BP1 
      activation in these tumors remains unknown. Therefore our aim in this study is to 
      assess the amplification status of the BP1 gene in breast cancer and to determine 
      whether BP1 protein expression is caused by gene amplification in these tumors. 
      BP1 amplification and expression were assessed in 36 samples. Twenty primary 
      breast tumors (PBT) and 14 sentinel lymph node (SLN) metastases were analyzed 
      using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), 
      respectively. Because of the close proximity of BP1 and HER2/NEU genes on 17q, 
      correlation between their amplification/expression was also investigated. 
      Increased BP1 copy number was observed in 33% of the cases, with a frequency of 
      36% and 29% in the PBT and SLN metastasis, respectively. BP1 protein was 
      expressed in 91% of the samples: in all of the PBT with increased BP1 copy number 
      and 65% of PBT with normal copy number. HER2/NEU amplification was detected in 
      22% of the cases. Concordance between BP1 and HER2/NEU copy numbers was found in 
      68% of the PBT and 90% of the SLN metastasis. In conclusion, we demonstrated that 
      the BP1 homeobox gene is amplified in breast cancer, both in PBT and SLN 
      metastasis, with a significant correlation with HER2/NEU amplification. 
      Considering that BP1 expression was observed in cases with both increased and 
      normal BP1 copy number, we conclude that other mechanisms in addition to gene 
      amplification play a role in BP1 protein expression.
FAU - Cavalli, Luciane R
AU  - Cavalli LR
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University, 3800 Reservoir Rd, Room S165A - LL Lombardi Building, Washington, DC 
      20007, USA. lrc@georgetown.edu
FAU - Man, Yan-Gao
AU  - Man YG
FAU - Schwartz, Arnold M
AU  - Schwartz AM
FAU - Rone, Janice D
AU  - Rone JD
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Urban, Cicero A
AU  - Urban CA
FAU - Lima, Rubens S
AU  - Lima RS
FAU - Haddad, Bassem R
AU  - Haddad BR
FAU - Berg, Patricia E
AU  - Berg PE
LA  - eng
GR  - P30 CA051008/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (DLX4 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Neoplasm Metastasis/genetics/pathology
MH  - Receptor, ErbB-2/genetics
MH  - Sentinel Lymph Node Biopsy
MH  - Transcription Factors/*genetics
PMC - PMC5806607
MID - NIHMS927728
EDAT- 2008/11/11 09:00
MHDA- 2008/12/31 09:00
PMCR- 2018/02/09
CRDT- 2008/11/11 09:00
PHST- 2008/05/09 00:00 [received]
PHST- 2008/07/18 00:00 [revised]
PHST- 2008/07/23 00:00 [accepted]
PHST- 2008/11/11 09:00 [pubmed]
PHST- 2008/12/31 09:00 [medline]
PHST- 2008/11/11 09:00 [entrez]
PHST- 2018/02/09 00:00 [pmc-release]
AID - S0165-4608(08)00459-7 [pii]
AID - 10.1016/j.cancergencyto.2008.07.004 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2008 Nov;187(1):19-24. doi: 
      10.1016/j.cancergencyto.2008.07.004.